Emerging Therapies for Nonmetastatic CRPC

Emerging Therapies for Nonmetastatic CRPC

Data From the Genitourinary Cancers Symposium in San Francisco

Not a member of My prIME? Join now for instant access.

Update your treatment options with this thought-leader discussion on nonmetastatic castration-resistant prostate cancer, with associated slide deck and eNewsflash, featuring valuable updates and expert perspectives on exciting new developments in the management of nonmetastatic castration-resistant prostate cancer released at the 2018 Genitourinary Cancers Symposium.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

CME

CME

0.5 AMA PRA Category 1 Credits

Newsflash

Newsflash

Release Date

Release Date

Apr 27, 2018

Expiration Date

Apr 27, 2019

Abstract #3: PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC)

Abstract #161: SPARTAN, a phase 3 double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC)

  • Robert Dreicer, MD, MACP, FASCOUniversity of Virginia Cancer Center
    Charlottesville, Virginia, United States
  • Neal Shore, MD, FACSCarolina Urologic Research Center
    Atlantic Urology Clinics
    Myrtle Beach, South Carolina

The proposed educational activity is specifically designed to meet the needs of global medical oncologists, urologists as well as other healthcare professionals involved in the treatment of patients with prostate cancer.

After successful completion of this educational activity, participants should be able to:

  • Discuss efficacy and safety data from recent clinical trials assessing second-generation hormonal therapies in castration-resistant prostate cancer (CRPC)
  • Develop optimal treatment selection and sequencing strategies to incorporate second-generation hormonal therapies into clinical practice

This is an indpendent educational activity supported by a grant from Astellas and Medivation, Inc., a Pfizer company.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Emerging Therapies for Nonmetastatic CRPC - prIME Oncology

prIME Oncology designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

Links to the posttest are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with 75% or higher.

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Dreicer has disclosed that he has received consulting fees from Astellas, AstraZeneca, Bristol-Myers Squibb, EMD Serono, Incyte, Orion, and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Shore has disclosed that he has received consulting fees from AstraZeneca, Bayer, Janssen, Pfizer, and Sanofi. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Ronald Viggiani, MD (medical director content reviewer/planner) – no relevant financial relationships
  • Amy Furedy, RN, OCN (clinical content reviewer/planner) – no relevant financial relationships
  • Heather Tomlinson, ELS (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.